Loading...

We've got a brand new version of Simply Wall St! Try it out

Cresco Labs

CNSX:CL
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CL
CNSX
CA$616M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Cresco Labs Inc. cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Cresco Labs has significant price volatility in the past 3 months.
CL Share Price and Events
7 Day Returns
-12.8%
CNSX:CL
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:CL
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
CL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cresco Labs (CL) -12.8% -11.5% -36.8% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on CL.
  • No trading data on CL.
Price Volatility
Industry
5yr Volatility vs Market

CL Value

 Is Cresco Labs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cresco Labs. This is due to cash flow or dividend data being unavailable. The share price is CA$9.16.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cresco Labs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cresco Labs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:CL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.14
CNSX:CL Share Price ** CNSX (2019-09-20) in CAD CA$9.16
CNSX:CL Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $6.91
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cresco Labs.

CNSX:CL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:CL Share Price ÷ EPS (both in USD)

= 6.91 ÷ -0.14

-47.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cresco Labs is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Cresco Labs is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Cresco Labs's expected growth come at a high price?
Raw Data
CNSX:CL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -47.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
197.7%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cresco Labs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cresco Labs's assets?
Raw Data
CNSX:CL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $2.45
CNSX:CL Share Price * CNSX (2019-09-20) in CAD CA$9.16
CNSX:CL Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $6.91
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:CL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:CL Share Price ÷ Book Value per Share (both in USD)

= 6.91 ÷ 2.45

2.82x

* Primary Listing of Cresco Labs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cresco Labs is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Cresco Labs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cresco Labs has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CL Future Performance

 How is Cresco Labs expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
197.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cresco Labs expected to grow at an attractive rate?
  • Cresco Labs's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Cresco Labs's earnings growth is expected to exceed the Canada market average.
  • Cresco Labs's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:CL Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:CL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 197.7%
CNSX:CL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 57.1%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:CL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:CL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 831 1
2021-12-31 924 262 2
2020-12-31 639 116 155 6
2019-12-31 173 -38 -22 7
2019-09-22
CNSX:CL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 78 -20 -14
2019-03-31 57 -16 -12
2018-12-31 41 -10 -2
2018-09-30 28 -5 4
2018-06-30 19 -7 1
2018-03-31 13 -6 1
2017-12-31 10 -5 -3
2016-12-31 3 -11 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cresco Labs's earnings are expected to grow significantly at over 20% yearly.
  • Cresco Labs's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:CL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Cresco Labs Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.37 0.37 0.37 1.00
2019-12-31 -0.09 0.02 -0.27 4.00
2019-09-22
CNSX:CL Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.14
2019-03-31 -0.15
2018-12-31 -0.03
2018-09-30 0.02
2018-06-30 0.01
2018-03-31 0.03
2017-12-31 -0.12
2016-12-31 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cresco Labs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cresco Labs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cresco Labs has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CL Past Performance

  How has Cresco Labs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cresco Labs's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cresco Labs does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Cresco Labs's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cresco Labs's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cresco Labs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cresco Labs Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 77.91 -13.76 64.44
2019-03-31 56.86 -11.81 47.84
2018-12-31 41.33 -1.92 33.13
2018-09-30 28.16 4.24 12.20
2018-06-30 18.78 1.33 8.88
2018-03-31 12.91 0.96 6.54
2017-12-31 10.31 -3.18 5.24
2016-12-31 3.16 -7.72 3.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cresco Labs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cresco Labs has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cresco Labs improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cresco Labs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cresco Labs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CL Health

 How is Cresco Labs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cresco Labs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cresco Labs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cresco Labs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cresco Labs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Cresco Labs has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cresco Labs Company Filings, last reported 2 months ago.

CNSX:CL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 272.38 0.00 61.13
2019-03-31 277.33 0.00 106.09
2018-12-31 282.98 0.00 131.30
2018-09-30 140.15 0.00 93.92
2018-06-30 67.21 0.19 31.70
2018-03-31 35.94 0.33 27.04
2017-12-31 35.94 0.33 27.04
2016-12-31 9.20 0.56 1.30
  • Cresco Labs has no debt.
  • Cresco Labs currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cresco Labs has less than a year of cash runway based on current free cash flow.
  • Cresco Labs has less than a year of cash runway if free cash flow continues to grow at historical rates of 75.3% each year.
X
Financial health checks
We assess Cresco Labs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cresco Labs has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CL Dividends

 What is Cresco Labs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cresco Labs dividends.
If you bought CA$2,000 of Cresco Labs shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cresco Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cresco Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:CL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:CL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cresco Labs has not reported any payouts.
  • Unable to verify if Cresco Labs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cresco Labs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cresco Labs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cresco Labs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cresco Labs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cresco Labs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CL Management

 What is the CEO of Cresco Labs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Charlie Bachtell
AGE 41
CEO Bio

Mr. Charles Bachtell, also known as Charlie, serves as Co-Founder and Chief Executive Officer at Cresco Labs, LLC and has been its Director since November 30, 2018. He served as an Executive Vice President and General Counsel at Guaranteed Rate, Inc. until March 2015. Mr. Bachtell served as the head of the legal and loss mitigation departments at Guaranteed Rate. He managed matters concerning legal, regulatory / legislative compliance, credit risk, corporate governance and acquisitions, among others. Additionally, he is a board member of the Guaranteed Rate Foundation, the company’s nonprofit (501 c3) arm. Mr. Bachtell worked with Guaranteed Rate since 2007. He obtained his Bachelor of Science degree in business administration with an emphasis in finance from the University of Arizona from 1996 to 2000 and his Juris Doctor from DePaul University College of Law.

CEO Compensation
  • Insufficient data for Charlie to compare compensation growth.
  • Insufficient data for Charlie to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Charlie Bachtell

TITLE
Co-Founder
AGE
41

Brian McCormack

TITLE
Co-Founder & Vice-Chairman
AGE
51

Joe Caltabiano

TITLE
President
AGE
42

Dominic Sergi

TITLE
Co-Founder & Director
AGE
36

Rob Sampson

TITLE
Co-Founder & Director
AGE
45

Ken Amann

TITLE
Chief Financial Officer
AGE
48

David Ellis

TITLE
Chief Operating Officer
AGE
37

Mo Dastagir

TITLE
Chief Information Officer
TENURE
0.2 yrs

Aaron Miles

TITLE
Vice President of Investor Relations

John Schetz

TITLE
General Counsel
AGE
42
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Cresco Labs board of directors in years:

0.8
Average Tenure
51
Average Age
  • The average tenure for the Cresco Labs board of directors is less than 3 years, this suggests a new board.
Board of Directors

Tom Manning

TITLE
Chairman
AGE
63
TENURE
0.7 yrs

Charlie Bachtell

TITLE
Co-Founder
AGE
41
TENURE
0.8 yrs

Brian McCormack

TITLE
Co-Founder & Vice-Chairman
AGE
51

Joe Caltabiano

TITLE
President
AGE
42
TENURE
0.8 yrs

Dominic Sergi

TITLE
Co-Founder & Director
AGE
36
TENURE
0.8 yrs

Rob Sampson

TITLE
Co-Founder & Director
AGE
45
TENURE
0.8 yrs

Gerry Corcoran

TITLE
Director
AGE
64
TENURE
2.4 yrs

John Walter

TITLE
Director
AGE
72
TENURE
2.4 yrs

Randy Podolsky

TITLE
Director
AGE
64
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
07. May 19 Buy Corcoran Family Foundation., Endowment Arm Company 25. Apr 19 25. Apr 19 7,750 CA$12.94 CA$100,275
04. Feb 19 Sell David Ellis Individual 29. Jan 19 29. Jan 19 -6,500 CA$9.15 CA$-59,475
17. Dec 18 Buy David Ellis Individual 10. Dec 18 10. Dec 18 6,500 CA$5.25 CA$34,125
X
Management checks
We assess Cresco Labs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cresco Labs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CL News

Simply Wall St News

Should You Be Concerned About Cresco Labs Inc.'s (CNSX:CL) ROE?

Our data shows Cresco Labs has a return on equity of 2.5% for the last year. … One way to conceptualize this, is that for each CA$1 of shareholders' equity it has, the company made CA$0.025 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

CL Company Info

Description

Cresco Labs Inc. cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flower, vape pens, and various forms of extracts under the cresco and Reserve brands; precisely-dosed and non-combustible products, including tinctures, capsules, salves, sublingual oils, and transdermal patches under the Remedi brand; culinary-backed and cannabis-infused edibles under the Mindy’s Artisanal brand; and fruity confections under the Mindy’s Kitchen brand. As of June 12, 2019, it operated 20 dispensaries in Florida. The company is headquartered in Chicago, Illinois.

Details
Name: Cresco Labs Inc.
CL
Exchange: CNSX
Founded:
CA$615,768,450
67,223,630
Website: http://www.crescolabs.com
Address: Cresco Labs Inc.
400 West Erie Street,
Suite 110,
Chicago,
Illinois, 60654,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX CL Subordinate Voting Shares Canadian National Stock Exchange CA CAD 03. Dec 2018
OTCPK CRLB.F Subordinate Voting Shares Pink Sheets LLC US USD 03. Dec 2018
DB 6CQ Subordinate Voting Shares Deutsche Boerse AG DE EUR 03. Dec 2018
Number of employees
Current staff
Staff numbers
1,400
Cresco Labs employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 01:02
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/09/20
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.